United Therapeutics CEO’s 10b‑5 Plan Trades: Insight on Insider Buying and Selling

Insider Activity at United Therapeutics: A Close‑Look at the CEO’s Trades

1. Contextualising the Latest Transaction

On 24 September 2026, Martine A. Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics, executed a series of trades that have attracted investor scrutiny. She purchased 9 500 shares of the company’s common stock at $117.76 per share, raising her post‑transaction holdings to 333 943 shares. The purchase was conducted under a pre‑arranged 10b‑5 (1) trading plan that is scheduled to remain in effect until the earlier of 15 March 2027 (option expiry) or 31 December 2026.

In the same trading session, Rothblatt sold multiple blocks of option‑derived shares, ranging in size from 40 shares to 1 480 shares, at market prices between $469.11 and $478.61. These sales reduced her net holdings to 325 083 shares. The pattern of large block purchases followed by equally large sales at market price is consistent with a routine portfolio‑rebalancing strategy rather than opportunistic speculation.

2. Implications for Investors

The trading pattern reflects a disciplined, systematic approach. A 10b‑5 (1) plan mandates that trades are pre‑scheduled and insulated from material non‑public information. Consequently, the trades are unlikely to signal a shift in the CEO’s confidence or the anticipation of a material corporate event.

Nevertheless, the consistency of the plan, coupled with United Therapeutics’ recent quarterly performance and the broader cyclical dynamics of the biotech sector, merits vigilance. Should future filings reveal a trend toward net buying, or a modification to the plan’s terms, such changes could be interpreted as an endorsement of the company’s pipeline and market prospects.

3. Historical Trading Profile

A review of Rothblatt’s filing history over the preceding week shows a repetitive pattern of buying 9 500 shares at $117.76 on multiple dates (14–24 September). She has also sold blocks ranging from 240 to 4 269 shares at prices between $492 and $505. The average sell price has trended upward from the $480 level on 24 September to the mid‑$500 range earlier in the week, indicating that she has been able to realize gains as the stock has recovered from a recent 3.9 % weekly decline.

Her holdings are held through family trusts and other entities, a structure that preserves alignment of interests while mitigating direct exposure. Historically, her transactions have been evenly balanced, underscoring a risk‑averse and disciplined approach.

4. Broader Insider Activity

Other senior executives, including EVP Paul Mahon, also sold sizable blocks of stock in mid‑September, at higher price points ($495–$502). The collective selling activity among senior insiders during this period reflects a broader market trend of portfolio rebalancing rather than a coordinated exit. No significant “sell‑off” spikes or abnormal trading volume were observed on the Nasdaq exchange, reinforcing the view that these transactions are routine.

5. Strategic Take‑Aways for the Future

Overall, Martine Rothblatt’s latest transactions appear to be part of a disciplined, pre‑planned rebalancing strategy. For investors, the moves reinforce the CEO’s alignment with United Therapeutics’ long‑term prospects rather than a short‑term opportunistic play.

Transaction Summary Table (Selected Trades on 24 September 2026)

Additional holdings are maintained through various trust structures and are not detailed here for brevity.